Genetic Signatures (GSS) Partnership summary
Event summary combining transcript, slides, and related documents.
Partnership summary
21 Jul, 2025Opening remarks and agenda
Announced a strategic partnership to deliver enhanced, scalable, fully automated infectious disease testing solutions.
Initial project phase has commenced with all partners actively involved.
Objectives of the partnership
Aim to simplify and scale syndromic molecular diagnostics globally.
Deliver a fully integrated, sample-to-answer ecosystem for infectious disease testing.
Partner introductions and roles
Tecan provides scalable liquid handling automation platforms.
Repado supplies modular, compliant IVD software for regulatory standards.
Genetic Signatures contributes its infectious disease assay portfolio.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Genetic Signatures
- Revenue up to $8.7m, margin down, with U.S./EMEA growth and cost discipline in focus.GSS
H1 202625 Feb 2026 - Sales up 136% to $8.5M, gross margin 59%, loss $15.2M, US launch delayed, $40.8M cash.GSSH1 202524 Dec 2025
- Revenue up 63% to $15.9m, gross margin 55%, first US contracts, and $30.9m cash reserves.GSSH2 202523 Nov 2025
- FY25 revenue up 66% to $14.4m, with record Q1 FY26 sales and all AGM resolutions approved.GSSAGM 2025 Presentation16 Nov 2025
- Sales up 20% sequentially, strong US contracts, and $28.2M cash support global expansion.GSSQ1 2026 TU20 Oct 2025
- Quarterly sales rose 52% sequentially, with strong cash reserves and new US contracts signed.GSSQ4 2025 TU21 Jul 2025
- Sales up 294% year-over-year, with $41.3M cash and strong US market momentum.GSSQ1 2025 TU13 Jun 2025
- FDA clearance for the GI Parasite Kit positions Genetic Signatures for US market growth.GSSH2 202413 Jun 2025
- FDA clearance and A$30m raise position Genetic Signatures for major US diagnostics expansion.GSSInvestor Presentation13 Jun 2025